Current PAH treatments improve outcomes, but remission remains a critical gap. Experts call for novel biomarkers, refined trial designs, & targeting reverse remodeling to optimize patient care. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

From @jama.com: Among adults with advanced chronic #kidney #disease (#CKD) stage 4 or 5 or on #dialysis, low-dose rivaroxaban did not lower #cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. ja.ma/4uOPe1P

A recent retrospective cohort study explored the frequency of elevated biomarkers & new clinical cardiac diagnoses in patients hospitalized with influenza or Covid-19. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

In a randomized trial, #Email recruitment increased research participant engagement more than patient portal messaging; message content (altruistic vs individualistic) had no significant overall effect. ja.ma/3Rp5eJ6

In acute #HeartFailure, a risk-stratified emergency department and postdischarge care strategy was equally effective in both females and males for reducing cardiovascular hospitalization or death. ja.ma/49BflAE

The spring issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here ➡️: tinyurl.com/65fbuvfa

❤️ Looking for resources in honour of Heart Failure Awareness Week? Don’t miss our curated collection of articles! ⬇️ ccs.ca/wp-content/u... #CardioSky #CJC #CJCO #CJCPC

In this highlighted review, Dr. Sean van Diepen & co-authors examine epidemiological data to propose a framework for the classification & management of mixed cardiogenic shock. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...

New peer‑reviewed research led by the Precision Health Alliance, coordinated by DCRI, outlines the ethical and regulatory considerations for responsibly advancing gene-editing therapies in precision medicine. dcri.org/news/new-pub... #ClinicalResearch #PrecisionMedicine #GeneEditing #Bioethics

The STRIVE trial found low-dose alteplase does not reduce microvascular obstruction in high-risk STEMI patients. With no clinical advantage & potential safety risks, routine use is not recommended. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

Currently accepting applications for the CVC Scholar Program! 🔬 This program is a unique training opportunity to enhance your research expertise & career in cardiovascular medicine. Learn more & apply here: thecvc.ca/programs-and... #CardioSky

Among Medicare beneficiaries, acute myocardial infarction incidence declined during and after the COVID-19 pandemic; mortality increased during the pandemic and then improved, especially in urban populations. ja.ma/48eNu8I

Management of brain–heart multimorbidity guideline: This clinical practice guideline expands on current cardiovascular guidelines to include evidence from the neurologic and mental health literature. ➡️ www.cmaj.ca/lookup/doi/10.1503/cmaj.251137

Alberta data shows maternal asthma increases risks of preterm birth, low birth weight, & C-sections—with highest risks tied to active asthma & specific inflammatory phenotypes. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

New meta-analysis data suggests rethinking transfusion strategies for patients with heart attack & anemia. Restrictive strategies were linked to higher cardiac mortality & lower 6-month survival. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...

Pooled data from the VICTOR & VICTORIA trials demonstrates vericiguat reduces CV death & HF hospitalizations across the HFrEF spectrum—from stable to recently worsened cases. Learn about this research & other highlights in the 2025 CVC Annual Report: thecvc.ca/annual-repor...

We spoke with Justin Ezekowitz, MD, to discuss his recent analysis of the SODIUM-HF trial, which indicated that dietary salt limitations may only benefit patients at the lowest risk for heart failure, contrary to popular belief. Watch now:

We’re pleased to share our 2025 Annual Report: The Arteries of Innovation. Innovation thrives on the circulation of diverse ideas. Discover how the CVC translates high-quality data into clinical solutions bridging the gap from discovery to care. Read the report here➡️: thecvc.ca/annual-repor...

Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. bit.ly/4alEy1P

Registration is open for the next webinar in our ASCVD Education Series, taking place Thursday, January 29, 2026, at 8:00 p.m. ET. Join us as experts explore evidence‑based strategies to enhance patient outcomes and support best practices in ASCVD management. Register today🔗https://bit.ly/3ZynKiT

In this @jamacardiology.com .com viewpoint, Drs. Armstrong, Bainey, & Granger advocate for aligning #STEMI time metrics with current first-point-of-contact capabilities to ensure optimized outcomes for all patients, regardless of geographic location. jamanetwork.com/journals/jam...

The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population. Explore more insights from the VICTOR trial ➡️ https://bit.ly/4blPC0O #HeartFailure

The winter issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here: mailchi.mp/bed47c9edc60...

Now accepting applications! The CVC Scholar Program is a unique training opportunity for early-stage investigators focused on cardiovascular disease research. Learn more & apply ➡️: thecvc.ca/programs-and... #cardiosky #cardiology

In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo @asnkidney.bsky.social | #KidneyWk

Congratulations to CVC Co-Director Dr. Padma Kaul, who has been named Tier 1 Canada Research Chair in Women and Children’s Cardio-Metabolic Health. 👏 www.ualberta.ca/en/the-quad/...

In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF. #cardiosky #medsky #LVEF #cardiology eurointervention.pcronline.com/article/impa...

🚨 Just published! This guideline provides multi-disciplinary clinical teams with practical recommendations for SGLT2is, MRAs, ARNI and drugs with GLP-1 receptor agonist activity. Read the guideline here: onlinecjc.ca/article/S082... #Cardiosky #HeartFailure

At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF. Watch now:

❣️The Fall 2025 issue of the CVC Chronicle newsletter is now available❣️ Read about our current trials, research highlights, & other recent news/updates here: tinyurl.com/3w4srx67

Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section, highlighting the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social @stollerykids.bsky.social @ualberta.bsky.social

Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do! @cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social

New analysis published in @jcardfail.bsky.social: applying the 5-STAR risk stratification method to VICTORIA trial data revealed a greater treatment effect for vericiguat on the composite endpoint of CV death or HF hospitalization. Read more ➡️: authors.elsevier.com/a/1llYy3pkRz...

Happy to have had the chance to contribute to this amazing collaborative work led by @sandeepsahaymd.bsky.social and Dr Ray Benza

Heart failure affects more than 55 million people worldwide. 🫀 A new Lancet Series, presented at #ESC2025, serves as a call to action for clinicians, health systems, and governments to prioritise the primary prevention of heart failure. tinyurl.com/2sty9386

Late-breaking science from VICTOR & VICTORIA trials presented at #ESCCongress add to growing body of evidence surrounding vericiguat in treating patients with HFrEF. Read more: https://bit.ly/4lTUNXE #HeartFailure

In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp #JACC #ESCCongress #WCCardio

The AURORA study is currently recruiting adults & adolescents with type 1 diabetes (T1D) & caregivers for an advisory group. Share your experience navigating the Alberta healthcare system & help us create a vital T1D knowledge hub! Learn more ➡️: thecvc.ca/aurora-recru...

Excited to finally share our James Lind Alliance #Top10 Research Priorities for #LungTransplantation 🫁🔬👩🏽‍🔬 @ualberta.bsky.social @ubcmedicine.bsky.social @umontreal.ca @uhnresearch.ca @ucalgarymed.bsky.social www.jhltopen.org/article/S295...

Patients hospitalized with influenza are just as likely as COVID-19 patients to have signs of myocardial involvement. Lead study author Finlay McAlister said the findings show a need to screen and monitor patients more closely. www.tctmd.com/news/cardiac...

New in @jaccjournals.bsky.social: A secondary analysis of the VICTORIA trial investigates the impact of geographic variation and Human Development Index on heart failure outcomes. 🫀 🌏 Read more here: www.sciencedirect.com/science/arti...

💭 Review of transcatheter aortic valve insertion (#TAVI) clinician opinions on the CCS Post-TAVI Driving Guidelines: is a 1-month driving restriction period overly cautious? Read more ⬇️ cjcopen.ca/article/S258... #CJCO #OpenAccess

Among patients with opioid-associated out-of-hospital cardiac arrest, chest compression and ventilation CPR was associated with a higher odds of favorable neurologic outcomes at hospital discharge. ja.ma/4l7We4q

Dr. Jason Weatherald explains how your everyday clinic visits can help shape the future of pulmonary hypertension treatment. @phaware.bsky.social podcast ep 524 @phacanada #phawareMD @teamphhope @albertaphdoc.bsky.social @ualberta.bsky.social medium.com/p/im-aware-t...

🫀 Join us June 11 for our webinar: Heart-Healthy Eating: Evidence-Based Nutrition for Cardiovascular Health! 🔗 Register now! ow.ly/yBOO50W5aZP #cardiosky

Dr. Padma Kaul will lead a #OneChildEveryChild program exploring how clinical, genetic, socio-economic, & behavioral factors impact neonatal & early childhood outcomes following pregnancy complications. @wchriuofa.bsky.social Read more about the OCEC initiative ⬇️ www.ucalgary.ca/news/ucalgar...

❣️The Spring 2025 issue of the CVC Chronicle newsletter is now available ❣️ Read about our current trials, research highlights, & other recent news/updates here: mailchi.mp/3fed258d1c05...

New research: Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section. These findings highlight the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social Read here: www.sciencedirect.com/science/arti...

Featured CJC Open article from CVC authors highlights the substantial and likely rising cost of heart failure hospitalizations in Canada, underscoring the urgent need for strategic solutions. Read here ▶️: www.cjcopen.ca/article/S258... #HeartFailureWeekCan

New online! Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism #CardioSky